Albany Molecular Research Inc.

Mark T. Frost is AMRI’s Senior Vice President, Administration and Chief Financial Officer. Prior to joining AMRI in December 2004, he was vice president of finance for Smith & Nephew Endoscopy, a global medical device division of S&N PLC, where he oversaw all financial aspects of the business. Prior to Smith & Nephew, he spent 14 years in progressively responsible positions at General Electric Company, culminating in his appointment as chief financial officer of GE Capital's Groupe Sovac Auto Financial Services in Paris, France. Prior to becoming CFO, Mark had been director of financial planning and analysis. Earlier, he was deputy managing director and chief financial officer of GE Capital's joint venture in Thailand. Mark also has held positions within GE Medical, GE's Corporate Audit Staff, and he completed GE's Financial Management Program. He received a B.A. with honors in International Relations/Economics from Colgate University, and conducted graduate coursework at INSEAD.

Dr. Trova received undergraduate training at Rensselaer Polytechnic Institute (B.S. 1983) followed by a doctorate in organic chemistry from the Ohio State University in 1987. After two years of postdoctoral research at the Massachusetts Institute of Technology, he became a staff scientist in the medicinal chemistry department of the Medical Research Division of the American Cyanamid Company, where he contributed to Cyanamid's discovery efforts in the anti-inflammatory, antiviral, and anti-cancer programs. Dr. Trova was recruited in August 1995 to Albany Molecular Research, Inc. as Assistant Director of Medicinal Chemistry. Dr. Trova was responsible for directing the research efforts of a group of medicinal chemists (4-8 scientists/technicians) who were involved with a number of projects. Dr. Trova was promoted in August 1996 to Director of Chemistry, Medicinal Chemistry with significantly increased responsibilities (20-25 scientists/technicians). In March of 1998, he was promoted to Vice President, Medicinal Chemistry and then in August 2000, another promotion led him to Senior Vice President. Projects of current interest under his direction are in the areas of cardiovascular diseases, inflammation, diabetes, CNS disorders, oncology, and ocular disorders. Areas of research interest to Dr. Trova include asymmetric synthesis, heterocycles, medicinal chemistry, and natural product synthesis. His current responsibilities include management of the Discovery Services of AMRI in the United States, Hungary and Singapore. A member of the American Chemical Society since 1982, Dr. Trova is a member of the Organic and Medicinal Chemistry divisions within the ACS. He is also a member of the American Association for the Advancement of Science, the New York Academy of Sciences, and the American Peptide Society.

Harold Meckler discovered the fun and enjoyment of synthetic organic chemistry while conducting undergraduate research in the laboratory of Professor Wilkins Reeves at the University of Maryland, College Park. Upon graduation, he moved to the laboratories of Professor Joseph Tufariello at the State University of New York at Buffalo, where he earned a Ph.D. in 1983. His thesis described the nitrone based syntheses of Anatoxin-a and Loline. Migrating 250 miles east to join the chemical development group of Sterling Winthrop (Rensselaer, New York), he worked on process modifications for the preparation of pentazocine (Talwin®). There, he examined the use of LiKOR (Schloesser) bases, amine boranes and modified sodium borohydride reducing agents for applications amenable to chemical production. In 1984, he moved to the chemical development group of CIBA-Geigy, where he focused on the process development, pilot plant scale up and cGMP production of a wide variety of compounds: aromatase inhibitors, adenosine antagonists, 5-lipoxygenase inhibitors, LTB4 inhibitors and ACE inhibitors. In addition, his lab groups were responsible for the production support of Forhistal®, Ismelin®, Anafranil®, Anturane®, Lioresal® and Lopressor®. In conjunction with these cGMP production activities, he was part of the two person team that wrote the Validation Guidelines for Bulk Pharmaceutical Chemicals for the CIBA-Geigy Pharmaceuticals Division. In 1994, he joined Telor Ophthalmic Pharmaceuticals to build its organic chemistry department. There, he designed the research and cGMP production labs, developed and implemented the synthesis of ethacrynic acid. Working with the analytical, QC and formulations groups, he developed and validated the Xarano® production procedures. In 1995, he joined Albany Molecular Research to head up the chemical development and GMP production groups. Since then, he has assumed broader responsibility as vice president, science and technology. He has received multiple patents as well as over fifteen publications.

Dr. Hagen is responsible for all Analytical Chemistry, Quality Assurance and Regulatory Affairs for all AMRI locations. He also oversees AMRI’s Chemical Development, Small Scale cGMP Manufacturing, and Large Scale Commercial Manufacturing business components, including operations in Albany/Rensselaer and Syracuse, New York; Hyderabad, India; as well as AMRI’s Large Scale Manufacturing operations in Rensselaer, New York and Aurangabad, India. Prior to this role, Dr. Hagen was Senior Director of Analytical Quality Services, where he supervised AMRI's analytical chemistry team, which measures the chemical purity and physical properties of drugs as they move through the drug development and manufacturing process. He joined AMRI in 2005 from his previous position as Director of Analytical Research and Development at Pfizer's Global Research and Development Division in Kalamazoo, Michigan. He began his tenure at Pfizer in 1994 as a Research Scientist. Prior to Pfizer, he was an Analytical Biochemist with Ribi ImmunoChem Research, Inc. Dr. Hagen received a B.A. in Biology from Lawrence University, as well as a Master's degree in Botany and a Ph.D. in Biochemistry, both from the University of Idaho.

Mr. Chester Opalka has been a director since 2003. Mr. Opalka is a co-founder of Albany Molecular Research, Inc. (AMRI), a drug discovery and development company focused on applications for the pharmaceutical, biotechnology and life sciences industries. Founded in 1991, AMRI is based in Albany, NY and employs over 800 people at sites in and around Albany and Syracuse NY and Seattle WA. Mr. Opalka retired from the daily operations of AMRI in September 2000 and retired from the AMRI board of directors in May 2002. Prior to founding AMRI, Mr. Opalka worked for Sterling Drug Inc. in various capacities in the Medicinal Chemistry and Chemical Development Departments since 1970. He has been named as inventor or co-inventor in nearly 30 patents, co-authored several scientific publications relating to his accomplishments in the field of pharmaceutical chemistry, including an invention that led to the marketed product, Inocor, a drug used to treat congestive heart failure. Mr. Opalka is a private investor and advises several start-up companies. He received his BS in Chemistry from Niagara University.

Thomas E. D'Ambra co-founded AMRI in 1991 and is chairman of the board, president and CEO. Previously, he was vice president, chemistry and co-founder of Coromed, Inc., as well as group leader and senior research chemist with Sterling Winthrop, Inc. He holds a Ph.D. from MIT.

Prior to joining AMRI, Dr. Guo was director, analytical development at Patheon. There, he managed a scientific staff of about 170 individuals at multiple locations responsible for supporting contract dosage form development and manufacturing services. He began his tenure at Patheon in 1999 in the role of supervisor, analytical development. Prior to Patheon, he worked at Genpharm, Inc. in Toronto, Canada in the areas of analytical R&D and technology transfer. Dr. Guo earned a Ph.D. in physical organic chemistry from The University of Western Ontario. He also holds a master’s degree in medicinal chemistry from the Chinese Academy of Medical Sciences in Beijing, and a bachelor’s degree in chemistry from Beijing Normal University.

Paul S. Anderson, a director since 2002, is former vice president at Bristol-Myers Squibb. Previously, he was VP for chemistry at Merck's West Point, PA facility, and senior VP for DuPont Pharmaceuticals. He has been involved in research leading to Zocor, Trusopt, Aggrastat, Crixivan and Sustiva. He has a Ph.D. from the University of New Hampshire.

Veronica G. H. Jordan, a director since 2006, most recently was CEO and president of Medelle Corporation. Previously, she was S.V.P. at Parexel International Corp. and director of marketing and business development at Biogen. She began her industry career at Baxter International, and holds a B.Sc. from Cambridge University and a Ph.D. from Oxford University.

Anthony P. Tartaglia, a director since 1995, was dean of Albany Medical College. Previously, he was executive director of the Albany Medical Center Hospital, senior vice president for patient care at Albany Medical Center, and chief of medicine at St. Peter's Hospital in Albany. He holds an M.D. from the University of Rochester.

Dr. Kuhla has served as a director since 1991. From 1998 through January 2004, Dr. Kuhla was president and chief operating officer of Albany Molecular Research, Inc., a chemical contract research organization, which Dr. Kuhla continues to serve as a director. From 1994 through 1998 Dr. Kuhla was vice president of Plexus Ventures, Inc., a business consulting firm. From 1990 to 1994, Dr. Kuhla held senior management positions with two venture capital-backed, biotechnology startup companies. His early career was spent in research and development and operations management positions with Pfizer Inc. and Rorer Group, Inc., his last position at Rorer being senior vice president of operations. Dr. Kuhla is a director of Synthetech Inc., a pharmaceutical fine chemical company. Dr. Kuhla received a Ph.D. degree in Organic Chemistry from Ohio State University.